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1. Introduction 
1.1 Adenosinergic pathways in the cardiovascular system 
Adenine-based purines, such as adenosine, and adenosine triphosphate (ATP), are 
ubiquitous signalling molecules that mediate diverse biological actions and physiological 
processes. Adenosine is an important signalling molecule in  the brain, lungs, kidneys, heart, 
blood vessels and immune systems (Lu et al., 2004), that exerts a potent action on many 
physiological processes including vasodilation, hormone and neurotransmitter release, platelet 
aggregation, and lipolysis (Baldwin et al., 2004; Podgorska et al., 2005). Reports of adenosine 
and adenosine monophosphate (AMP), effects on the heart and blood vessels (Drury & 
Szent-Gyorgyi, 1929), were the first in a major line of research concerning the physiological 
actions of purines. Since then, the list of biological processes in which extracellular purines 
participate has dramatically increased. Insights into the physiological roles of purines came 
from studies of their biological sources and the stimuli for their release.  
Adenosine is composed of an adenine base, consisting of two carbon-nitrogen rings, bound 
to a ribose sugar group via a beta glycosidic link (Fig. 1); it is considered a nucleoside due to 
the absence of phosphate groups in its structure. It presents a short half-life due to its rapid 
conversion into inosine by adenosine deaminase, phoshorylation by adenosine kinase and 
rapid uptake by adenosine transporters into tissues (Thorn & Jarvis, 1996).  
 
Fig. 1. Adenosine molecule. 
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Adenosine is a plurisystem mediator/modulator, influencing responses in various cell and 
tissue types, and via numerous receptor and cell signalling pathways. Adenosine can be 
generated by intracellular and extracellular enzyme pathways depending upon the specific 
and unique conditions, giving rise to elevated extracellular concentrations. Both 
equilibrative and concentrative adenosine transport proteins can move adenosine across 
cellular membranes, influencing extracellular adenosine concentrations (Conlon et al., 2005). 
There are several pools of adenosine which arise from different sources. Firstly, there is the 
existing adenosine being transported in and out of cells via transporters. ATP present in the 
cytosol is dephosphorylated to AMP which can be dephosphorylated further by the action 
of adenosine kinase to produce adenosine. Alternatively, ATP can be released from the cell 
by exocytosis, which can then be acted upon by nucleotidases to form adenosine 
diphosphate (ADP), then AMP and finally adenosine. It can then be transported between the 
inside of the cell and the interstitial fluid via transporters. Another pool of adenosine is 
generated by neurons. ATP, as a neurotransmitter can be released into the interstitial fluid 
when carrying a nerve impulse. As before, ATP is acted on by nucleotidases to ADP which 
is further hydrolysed to AMP and then adenosine (Rang et al., 2007). 
Under physiological conditions, adenosine is produced intracellularly (Fig. 2) by AMP 
dephosphorylation, and extracellularly (Fig. 2) by dephosphorylation of released adenine 
nucleotides (Brunton et al., 2006; Rang et al., 2007), mainly ATP (Conlon et al., 2005; Meghji 
et al., 1992). 
1.2 Adenosine receptors 
The intra and extracellular concentration of adenosine is determined, nearby their receptors, 
by the existence and function of the transporters. Adenosine is a potent modulator of 
cardiovascular function and when administered systemically, adenosine produces 
hypotension and bradycardia (Barraco et al., 1987; Evoniuk et al., 1987). These effects are 
thought to be mediated at adenosine receptors localized centrally (central nervous system) 
and in the periphery (heart and vasculature), through different receptor subtypes, 
particularly the adenosine A1 and A2A subtypes (Dhalla et al., 2003; Shryock & Belardinelli, 
1997; Spyer & Thomas, 2000; Tabrizchi & Bedi, 2001). In the periphery, A1 receptors are 
located primarily in the heart and mediate negative inotropic and chronotropic effects 
(Shryock & Belardinelli, 1997). Adenosine A2A receptors are located primarily in the 
vasculature and mediate vasodilation (Tabrizchi & Bedi, 2001). In the central nervous 
system, adenosine A1 receptors are widely distributed, while adenosine A2A receptors are 
found in limited regions of the brain, most prominently in the striatum (Dunwiddie & 
Masino, 2001). However, high levels of A2A receptors are also found in the cardiovascular 
regulation regions of the hindbrain, including the nucleus tractus solitarius and the rostral 
ventral lateral medulla (Thomas et al., 2000). In fact, adenosine A2A receptors are thought to 
play a neuromodulatory role in baroreceptor reflex control (Barraco et al., 1988; Schindler et 
al., 2005; Thomas et al., 2000). 
Adenosine receptors activation may alter vascular tonus in normotensive rats (Cox, 1979; 
Fresco et al., 2002; Fresco et al., 2004; Fresco et al., 2007), and its modulation differs in 
hypertensive rats. Thus, it is conceivable that the availability of adenosine may be altered in 
pathological conditions (Karoon et al., 1995), such as hypertension (Rocha-Pereira et al., 2009). 
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Fig. 2. Metabolism of Adenosine: extracellular. Partial schema of enzyme pathways involved 
in the regulation of extracellular adenosine concentrations. Cyclic adenosine 
monophosphate (cAMP) can be transported out of cells upon activation of adenylate 
cyclase. The actions of an ecto-phosphodiesterase on cAMP results in the formation 
of AMP. AMP can also be directly released by some cell types. AMP is acted upon by 
an ecto-5'-nucleotidase to form adenosine; it can then be transported into the cell, or 
deaminated to inosine by adenosine deaminase. Hypoxanthine is formed after removal 
of ribose from inosine by the actions of purine nucleoside 
phosphorylase. Hypoxanthine enters the xanthine oxidase pathway to sequentially 
form xanthine and uric acid, generating oxyradicals as a byproduct; Metabolism of 
Adenosine: intracellular. Partial schema of enzyme pathways involved in the regulation of 
intracellular adenosine concentrations. Adenosine monophosphate (AMP) can be directly 
deaminated to inosine monophosphate (IMP) by AMP deaminase, or acted upon by an 
endo-5'-nucleotidase to form adenosine; it can be rephosphorylated to AMP by adenosine 
kinase, or deaminated to inosine by adenosine deaminase. IMP can also be a source of 
inosine by the same endo-5'-nucleotidase. Hypoxanthine is formed after removal 
of ribose from inosine by the actions of purine nucleoside phosphorylase. Hypoxanthine can 
be salvaged to IMP by hypoxanthinephospho-ribosyltransferase, or by entering the xanthine 
oxidase pathway to sequentially form xanthine and uric acid, generating oxyradicals as a 
byproduct. Intracellular adenosine can be transported into and out of the cell by membrane-
associated transporter proteins. Being an endogenous purine nucleoside, adenosine is 
constitutively present in the extracellular spaces at low concentrations. However, its levels 
increase dramatically in blood and interstitial fluids (extracellular level), in response to cell 
injury and metabolically-stressful conditions such as tissue damage, hypoxia, ischemia and 
inflammation. Extracellular adenosine levels have been observed to increase by 
dephosphorylation of ATP and so a large amount of adenosine is produced from the 
breakdown of adenine nucleotides by ecto-5´-nucleotidase (Fig. 2) (Cronstein, 1994; Li et al., 
2009; Li et al., 2011); and then to be released through the action of specialized nucleoside 
transporters (Pastor-Anglada et al., 2001). 
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Fig. 3. Adenosine binding to purinergic receptors in smooth muscle tissue. Adenosine can 
bind to purinergic receptors in different cell types where it can produce diverse 
physiological actions. One important action is vascular smooth muscle relaxation, which 
leads to vasodilation. This mechanism is particularly important for matching coronary blood 
flow to the metabolic needs of the heart. In coronary vascular smooth muscle, adenosine 
binds to adenosine receptors A2A, which are coupled to the Gs-protein. Activation of this G-
protein stimulates adenylate cyclase, increases cAMP and causes protein kinase activation. 
This stimulates KATP channels, which hyperpolarize the smooth muscle, causing relaxation. 
Increased cAMP also causes smooth muscle relaxation by inhibiting myosin light chain 
kinase, which leads to decreased myosin phosphorylation and a decrease in contractile 
force. There is also evidence that adenosine inhibits Ca2+ entry into the cell through L-type 
Ca2+ channels. Since Ca2+ regulates smooth muscle contraction, reduced intracellular Ca2+ 
causes relaxation. In some types of blood vessels, there is evidence that adenosine produces 
vasodilation through increases in cGMP, which leads to inhibition of Ca2+ entry into the cells 
as well as opening of K+ channels. 
It is well established that adenosine effects occur via activation of specific membrane 
receptors, known as A1, A2A, A2B and A3 (Olsson & Pearson, 1990; Ralevic & Burnstock, 1998) 
that are currently accepted to be coupled to Gi/o, Gs, Gs/Gq and Gi/o/Gq, respectively 
(Fredholm et al., 2001). Adenosine receptors are broadly grouped into two categories: 
A1 and A3 receptors, which couple to inhibitory G proteins, and A2A and A2B receptors, 
which couple to stimulatory G proteins. However, adenosine receptors are pleiotropic; they 
can couple with various G proteins and transduction systems according to their degree of 
activation and their particular cellular or subcellular location (Cunha, 2005). 
1.2.1 Adenosine receptors and vasodilation 
Adenosine receptors are present in many areas of the organism including the smooth 
muscle cells of blood vessels - these subtypes of receptors have been found to be distributed 
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in different blood vessels such as the coronary artery, pulmonary artery, mesenteric artery, 
renal vasculature and aorta (Olah et al., 1995; Olah & Stiles, 1995).  
The importance of the adenosine induced vasodilatation (Fig. 3), is known in the coronary 
artery of many species including rats. The vasodilatory effect appears to be mediated by A2 
receptors on vascular smooth muscle cells, thus increasing blood flow and oxygenation; 
also, adenosine released during preconditioning by short periods of ischemia followed by 
reperfusion can induce cardioprotection to subsequent sustained ischemia (Li et al., 2011). 
There are two pathways which can result in relaxation. The first pathway is via activation of 
A2 receptors located on smooth muscle cells, which are linked to KATP sensitive channels, 
and the second is through activation of A2 receptors located on nitric oxide associated 
endothelial cells. Alternatively there are blood vessels such as the pulmonary artery in 
which vascular control is mediated via both A1 and A2 receptor activation, with 
vasoconstriction occurring via the activation of A1 receptors and vasodilatation mediated by 
the activation of A2 receptors (Tabrizchi & Bedi, 2001). A2 receptor agonists, including 5'-N-
ethylcarboxamide-adenosine, were investigated on porcine coronary artery by King and co-
workers (King et al., 1990), and their findings showed that these compounds caused 
vasodilation. These results support the idea that the activation of adenosine A2 receptors on 
smooth muscle results in adenosine-induced relaxation. On the other hand, no evidence has 
been linked to A3 receptor activation producing relaxation of blood vessels. Similar findings 
were obtained from a study by Hiley and co-workers (Hiley et al., 1995), which tested the 
effects of adenosine analogues on rat mesenteric artery which showed that adenosine 
analogue, 5'-N-ethylcarboxamide-adenosine acts on adenosine A2 receptors on the 
mesenteric bed to produce relaxation. In addition, relaxation mediated by adenosine 
receptors in the mesenteric bed was sensitive to inhibition by 8-(3-chlorostyryl)caffeine, a 
selective adenosine A2A receptor antagonist.  
Signalling of the adenosine receptor occurs via a G-protein coupled mechanism, with 
differences between the subtypes: the A1 subtype is thought to be coupled to Gi or Go 
proteins via inhibition of adenylate cyclase or activation of phospholipase C, respectively, 
and conducing to the opening of K+ channels and inhibition of Ca2+ channels; the A2A 
subtype (A2AR) interacts with the G protein Gs and the A2B subtype (A2BR) interacts with the 
G proteins Gs or Gq to induce adenylate cyclase activity and elevate cAMP levels and 
consequently, activating calcium channels; the A3 subtype couples to the Gi or Gq proteins 
through  activation of phospholipase C/D or  inhibition of adenylate cyclase, respectively 
(Olah & Stiles, 1995). 
It is conceivable that adenosine cardioprotective effect is mediated through the activation of 
adenosine receptors A1 and A3 in cardiomyocytes, and involves protein kinase C and 
mitochondrial KATP channels. However, a recent study has shown that A2B receptors may 
also be involved since adenosine A2B receptor-deficient mice are more susceptible to acute 
myocardial ischemia and the treatment of normal mice with an agonist of the receptor A2B 
significantly attenuated the infarct size after ischemia (Li et al., 2011). 
It has been established that adenosine receptor activation occurs via a series of signalling 
pathways as a result of the binding of adenosine. The affinity of these receptors for 
adenosine varies; thus their activation depends on the adenosine’s concentration. 
Metabolism and transport across the plasma membrane are the main factors influencing the 
adenosine level (Podgorska et al., 2005). 
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In summary, when adenosine binds to these receptors it can cause vascular smooth muscle 
relaxation leading to vasodilatation of blood vessels. As mentioned above, this occurs via a 
G-protein coupled protein mechanism. On activation of the G-protein, adenylate cyclase is 
activated causing an increase in cAMP concentration. This then leads to protein kinase A 
activation which stimulates K+ channels, hyperpolarizing smooth muscle, causing relaxation 
(Tawfik et al., 2005). 
1.3 Nucleoside transporters 
Membrane transporters are responsible for the uptake of essential nutrients, modulation of 
concentrations of physiologically relevant chemicals, and active release of substances such 
as signaling molecules (Hyde et al., 2001). Transmembrane transport is a critically important 
physiological process in all cells and, is likely to have evolved early to allow for controlled 
uptake and release of nonlipophilic compounds. Nucleoside Transporters constitute a 
family of membrane proteins with different pharmacological and kinetic properties 
(Fredholm, 2003), recently identified and characterized in humans. These transport proteins 
were initially purified from human blood red cells for more than two decades ago, and the 
lack of abundance of nucleoside transporters proteins in the membranes of mammalian 
cells, has hampered the analysis of the relationship between its structure and function 
(Endres et al., 2009; Molina-Arcas et al., 2008; Molina-Arcas et al., 2009). 
As previously discussed, there are several ways in which adenosine can be produced and 
made available for adenosine receptors. One of such, being the transport of adenosine across 
the plasma membrane, through nucleoside transporters, which determine the intra and 
extracellular levels of nucleosides, including adenosine (Baldwin et al., 2004; Lu et al., 2004). 
Generally, nucleoside transporters facilitate the movement of nucleosides and nucleobases 
across cell membranes but their distribution is not homogeneous among tissues, and their 
expression can be regulated by various physiological and pathophysiological conditions 
(Baldwin et al., 2004; Lu et al., 2004; Molina-Arcas et al., 2008). Over the past two decades 
important advances in the understanding of nucleoside transporters functioning have been 
achieved. One of nucleoside transporters functions is to salvage extracellular nucleosides for 
intracellular synthesis of nucleotides; besides, they also control the extracellular 
concentration of adenosine in the vicinity of its cell surface receptors and regulate processes 
such as neurotransmission and cardiovascular activity (Anderson et al., 1999; Cass et al., 
1999). Other function of nucleoside transporters is vital for the synthesis of nucleic acids in 
cells that lack de novo purine synthesis: carrier-mediated transport of this nucleoside plays 
an important role in modulating cell function, because the efficiency of the transport 
processes determines adenosine availability to its receptors or to metabolizing enzymes. 
Therefore, nucleoside transporters may be key elements as therapeutic targets in the 
cardiovascular disorders as they are, for example, in anticancer and antiviral therapy where 
nucleoside analogues are successfully used (Huber-Ruano & Pastor-Anglada, 2009; Lu et al., 
2004; Molina-Arcas et al., 2005; Yao et al., 2002). 
To date it is accepted that there are two types of transporters (Fig. 6) (Baldwin et al., 2004; 
Podgorska et al., 2005): 
• Equilibrative Nucleoside Transporters (ENT) – equilibrative bidirectional transport 
processes driven by chemical gradients by facilitated diffusion. ENT are present in 
www.intechopen.com
 
Adenosinergic System in the Mesenteric Vessels 115 
most, possibly all, cell types (Cass et al., 1998). They might mediate adenosine 
transporter in both directions, depending on the concentration gradient of adenosine 
across the plasma membrane. Until the present day, there are four subtypes described: 
ENT1, ENT2, ENT3 and ENT4 (Baldwin et al., 2004; Molina-Arcas et al., 2009; 
Podgorska et al., 2005). 
• Concentrative Transporters (CNT) – active inwardly directed concentrative processes, 
driven by the Na+ electrochemical gradient: Na+-dependent. CNT are expressed in a 
tissue-specific fashion (Cass et al., 1998). Three subtypes were described: CNT1, CNT2 
and CNT3 (Hyde et al., 2001; Kong et al., 2004; Molina-Arcas et al., 2009). 
Identification and molecular cloning of the ENT and CNT families from mammals and 
protozoan parasites have provided detailed information about the structure, function, 
regulation, tissue and cellular localization (Baldwin et al., 2004; Molina-Arcas et al., 2008). 
Comparing these different types of transporters, CNT and ENT, some differences become 
evident. Whereas the CNT transport processes are present primarily in specialized epithelia, 
the ENT transport processes are found in most mammalian cell types (Cass et al., 1998).  
Both types of transporters are tightly regulated, both by endocrine and growth factors and by 
substrate availability. They transport endogenous substrates such as adenosine, thymidine, 
cytidine, guanosine, uridine, inosine, and hypoxanthine (Lu et al., 2004). They are both 
involved in the transport of adenosine, but ENT have higher affinity for adenosine than CNT 
(Molina-Arcas et al., 2009), a reason why the present study focused exclusively on ENT. 
ENT play an important role in the provision of nucleosides, derived from the diet or 
produced by tissues such as the liver, for salvage pathways of nucleotide synthesis in those 
cells deficient in de novo biosynthetic pathways. The latter include erythrocytes, leukocytes, 
bone marrow cells and some cells in the brain. The co-existence in many cell types of both 
ENT1 and ENT2, which exhibit similar nucleoside specificities, may reflect the importance 
of the ENT2 substrate hypoxanthine as a source of purines for salvage. Similarly, this ability 
to transport hypoxanthine and the higher apparent affinity of ENT2 for inosine have been 
suggested to reflect a role in the efflux or uptake of these adenosine metabolites during 
muscle exercise and recovery respectively (Baldwin et al., 2004; Endres et al., 2009). Several 
polymorphisms have been described in ENT proteins that could affect nucleoside 
homeostasis, adenosine signalling events or nucleoside-derived drug cytotoxicity or 
pharmacokinetics (Kong et al., 2004; Molina-Arcas et al., 2009). Although the transport of 
adenosine involves a simple carrier system, it is a complex process. 
1.3.1 Equilibrative nucleoside transporters isoforms 
The first example of the ENT family was characterized in human tissues at the molecular 
level only 10 years ago. Since that time, the identification of homologous proteins by 
functional cloning and genome analysis has revealed that the family is widely distributed in 
eukaryotes. The SLC29 family of integral membrane proteins, is part of a larger group of 
equilibrative and concentrative nucleoside and nucleobase transporters found in many 
eukaryotes. ENT are a unique family of proteins with no apparent sequence homology to 
other types of transporters, which enable facilitated diffusion of nucleosides, such as 
adenosine, and nucleoside analogues across cell membranes (Hyde et al., 2001). Studies 
performed over the past thirty years have revealed that most mammalian cells exhibit low-
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affinity, ENT processes, now known to be mediated by members of the SLC29 family. Some 
mammalian ENT have been well characterized at the molecular and pharmacological levels 
(Crawford et al., 1998), and currently, four isoforms are known: ENT1–4 (Hyde et al., 2001).  
Human (h) and rat (r) ENT1 and ENT2 (456–457 amino acid residues) transport both purine 
and pyrimidine nucleosides, including ADO. They also differ in their sensitivity to 
vasodilator drugs (hENT1 > hENT2 > rENT1 > rENT2) and by the ability of hENT2 and 
rENT2 to transport nucleobases as well as nucleosides (Hyde et al., 2001).  
ENT family members are predicted to possess 11 transmembrane helices, with a cytoplasmic 
N-terminus and an extracellular C-terminus experimentally confirmed for ENT1 (Baldwin et 
al., 2004). The number of molecules present of each ENT subtype depends on both the cell 
and the tissue type. The intra and extracellular concentration of adenosine is determined, 
nearby their receptors, by the existence and function of the transporters, and the four 
isoforms although structurally similar, show differences in their ability to regulate 
adenosine concentrations, which may be due to slight modifications in configuration 
(Baldwin et al., 2004). 
Whilst the name of the family reflects the properties of its prototypical member ENT1, some 
family members can also transport nucleobases and some are proton-dependent, 
concentrative transporters. Therefore, the transporters play key roles in nucleoside and 
nucleobase uptake for salvage pathways of nucleotide synthesis, and are also responsible for 
the cellular uptake of nucleoside analogues. In addition, by regulating the concentration of 
adenosine available to cell surface receptors, they influence many physiological processes 
ranging from cardiovascular activity to neurotransmission (Baldwin et al., 2004). ENT are 
targets, for example, for coronary vasodilator drugs, are responsible for the cellular uptake 
of nucleoside analogues used in the treatment of cancers and viral diseases (Elwi et al., 2006; 
Young et al., 2008) and they can also act as routes for uptake of cytotoxic drugs in humans 
and protozoa (Hyde et al., 2001).  
The best-characterized members of the family, ENT1 and ENT2, are cell surface proteins that 
possess similar broad substrate specificities for purine and pyrimidine nucleosides 
regulating, eventually, the access of adenosine to its receptors. ENT1 plays a primary role 
mediating adenosine transport while ENT2, in addition, efficiently transport nucleobases 
(Baldwin et al., 2004). More recently, the ENT3 and ENT4 isoforms have been shown to be 
also genuine nucleoside transporters, they are both pH sensitive, and optimally active under 
acidic conditions. ENT3 has a similar broad permeant selectivity for nucleosides and 
nucleobases and appears to function in intracellular membranes, including lysosomes. ENT4 
is uniquely selective for adenosine, but yet present a low affinity to this nucleoside, and it 
may also transport a variety of organic cations (Baldwin et al., 2004; Kong et al., 2004).  
All four isoforms are widely distributed in mammalian tissues, although their relative 
abundance varies. In polarised cells ENT1 and ENT2 are found in the basolateral membrane 
and, in tandem with CNT of the SLC28 family, may play a role in transepithelial nucleoside 
transport. ENT2 is known to be particularly abundant in skeletal muscle while the ENT3 
isoform seems to be widely distributed and the most abundant ENT in the heart. 
Nevertheless, since ENT3 is a lysosomal transporter functioning in intracellular membranes, 
is unlikely to contribute to a direct regulation of interstitial adenosine concentrations in 
tissues. Finally, in what concerns the ENT4, it presents low sequence identity to the other 
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members of the family (due to differences in its structure), is highly selective for adenosine 
and is also widely distributed. For instance, ENT4 is present in vascular endothelial cells 
and contributes to regulate the extracellular concentration of adenosine in these structures 
but only at acidic pH (Baldwin et al., 2004; Barnes et al., 2006).  
In summary, all four members of the family share an ability to transport adenosine, but 
differ in their abilities to transport other nucleosides and nucleobases. 
The human gene encoding the human ENT1 (hENT1) protein has been localized to region 
p21.1-21.2 on chromosome 6 (Baldwin et al., 2004). hENT1 protein consists of 456-residue 
protein and its sequence displays about 78% identity to the 457-residue rat homologue 
(rENT1) and 79% identical to the 460-residue mouse protein (mENT1.1) homologues. Splice 
variants of hENT1 have not been reported, but a 458-residue variant of the mouse 
homologue (mENT1.2), generated by alternative splicing at the end of exon 7, is widely 
distributed (Abdulla & Coe, 2007).  
The two forms of mENT1 protein appear to be functionally identical, although mENT1.2 
lacks the potential casein kinase II phosphorylation site. Both rENT1 and hENT1 proteins 
display broad substrate specificity for pyrimidine and purine nucleosides with Km values 
ranging from 50 mM (adenosine) to 680 mM (cytidine), but are unable to transport the 
pyrimidine base uracil (Yao et al., 1997). hENT1 and mENT1, which are sensitive to 
nitrobenzylthioinosine (NBMPR), are also inhibited by the coronary vasodilators 
dipyridamole, dilazep, and draflazine. In contrast, rENT1 although presenting sensitivity to 
NBMPR is essentially insensitive to inhibition by the coronary vasodilators dipyridamole 
and dilazep (Baldwin et al., 2004; Podgorska et al., 2005; Ward et al., 2000; Yao et al., 1997). 
The messenger ribonucleic acid (mRNA) for hENT1 is widely distributed in different tissues, 
including erythrocytes, liver, heart, spleen, kidney, lung, intestine, and brain (Endres et al., 
2009; Griffith & Jarvis, 1996; Lum et al., 2000; Pennycooke et al., 2001). mENT1.2 protein was 
shown to be commonly co-expressed with mENT1.1 (460 aminoacids) and the highest level 
was found in the liver, heart and testis. Moreover, studies at both the mRNA and protein 
levels have revealed that ENT1 is almost ubiquitously distributed in human and rodent 
tissues, although its abundance varies between tissues (Baldwin et al., 2005).  
Human ENT2 (hENT2) protein, responsible for the ei type nucleoside transport, is encoded 
by a gene localized at position 13q on chromosome 11. hENT2 consists of 456 aminoacids 
and their sequence displays 88% identity to mouse (mENT2) and rat (rENT2) homologues. 
In humans, besides the 456-aminoacid ENT2 protein, exists at least, two shorter forms of 
ENT2, generated from mRNA splice variants. The 326 aminoacid protein, termed hHNP36, 
lacks the first three transmembrane domains and is inactive as a nucleoside transporter. 
Inactive is also the second splice variant, a 301-aminoacid protein named hENT2A that lacks 
the C-terminal domain (Crawford et al., 1998). 
The ENT2 protein accepts a broad range of substrates, including purine and pyrimidine 
nucleosides and nucleobases. It has been postulated that hENT2 plays a role in the efflux 
and reuptake of inosine and hypoxanthine generated from adenosine during and after 
strenuous physical exercise. ENT2 (both rat and human), is much less susceptible to inhibition 
by NBMPR and the coronary vasodilators dipyridamole and draflazinethan ENT1 (Baldwin et 
al., 2004; Crawford et al., 1998; Podgorska et al., 2005; Ward et al., 2000; Yao et al., 1997, 2002). 
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The mRNA for ENT2 was reported to be present in several tissues including heart, kidney, 
brain, placenta, thymus, pancreas, intestine and prostate, but the highest expression level was 
found in skeletal muscle (Crawford et al., 1998; Lum et al., 2000; Pennycooke et al., 2001). 
The gene encoding the human ENT3 (hENT3) protein is located at position q22.1 on 
chromosome 10. hENT3 is a 475-residue protein displaying 73% identity to the mouse 
homologue (mENT3) (Baldwin et al., 2004, 2005; Kong et al., 2004). ENT3 has a 
characteristic, long (51 aminoacids), hydrophilic N-terminal region preceding the first 
transmembrane (TM1) domain. The N-terminal region of ENT3 consists of two di-leucine 
motifs characteristic for endossomal, lysosomal targeting motifs. This architectural design 
distinguishes the ENT3 protein from other members of the equilibrative transporters family. 
Indeed, it was demonstrated that hENT3 protein is predominantly localized intracellularly 
and that mutation of the dileucine motif to alanine triggers the relocation of ENT3 protein to 
the cell surface (Baldwin et al., 2004, 2005). 
In comparison with ENT1, the ENT3 protein is much less susceptible to inhibition by 
NBMPR and coronary vasodilatory drugs (dipyridamole and dilazep). hENT3 demonstrates 
a broad selectivity for nucleosides, but does not transport hypoxanthine. Moreover, the 
hENT3 protein facilitates transport of several adenosine analogues like cordycepin (3’-
deoxyadenosine) (Baldwin et al., 2004; Podgorska et al., 2005). hENT3 and hENT4, which are 
mainly located in the intracellular organelles, are not prominent nucleoside transporters like 
hENT1 and hENT2 (Endo et al., 2007). 
The mRNA for ENT3 has been detected in a variety of mouse and human tissues, including 
brain, kidney, colon, testis, liver, spleen, placenta (highest level), and in a number of 
neoplastic tissues (Baldwin et al., 2004, 2005; Hyde et al., 2001). 
The gene encoding the human ENT4 (hENT4) protein is located on chromosome 7, at 
position p22.1. Interestingly, the hENT4 is more closely related to the products of the 
Drosophila melanogaster gene CG11010 (28% identity) and the Anopheles gambiae gene 
agCG56160 (30% identity), than to hENT1 (18% identity), indicating an ancient divergence 
from the other members of the SLC29 family (Acimovic & Coe, 2002). hENT4 is a 530-
residue protein 86% identical in sequence to its 528-residue mouse homologue (mENT4) 
(Baldwin et al., 2004). The substrate specificity of hENT4 has not yet been established in 
detail, but among the ENT proteins, hENT4 has the lowest affinity for adenosine (Kong et 
al., 2004). The mRNA for hENT4 was detected in several human tissues. However, recent 
characterisation of the complementary deoxyribonucleic acids (cDNAs) encoding h/mENT4 
has confirmed that these proteins are indeed nucleoside transporters, capable of low-affinity 
adenosine transport. Analysis of multiple tissue RNA arrays indicates that hENT4 is likely 
to be ubiquitously expressed in human tissues (Baldwin et al., 2005; Podgorska et al., 2005). 
1.3.2 Equilibrative nucleoside transporters in the cardiovascular system 
There are currently no reports implicating ENT - SLC29 transporters family, in the 
pathogenesis of human disease (Baldwin et al., 2004). Still, as mentioned above, adenosine 
transporters contribute to the intra and extracellular concentration of adenosine, modulating 
its concentration in the vicinity of its receptors (Li et al., 2011; Tawfik et al., 2005). It is 
therefore conceivable that the availability of adenosine may be altered in pathological states. 
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Adenosine exerts vasodilatory and cardioprotective effects, and also reduces the 
proliferation of vascular smooth muscle cells, inhibits platelet aggregation and attenuates 
the inflammatory response. Apart from adenosine receptors and ecto-5´-nucleotidase, 
transporter proteins can regulate adenosine function by modulating extracellular levels of 
adenosine. The extracellular adenosine is rapidly taken up into cells by nucleoside 
transporters and is, subsequently, metabolized to inosine by adenosine deaminase and 
phosphorylated to AMP by adenosine kinase. Nucleoside transporters are supposed to play 
an integral part in adenosine functions by “fine-tuning” local levels of adenosine in the 
vicinity of adenosine receptors (Li et al., 2011).  
Recent studies have proposed the occurrence of a greater degree of adenosine release from 
cells that are metabolically stressed. In other words, cells with a high oxygen demand such 
as the vascular smooth muscle cells in the hypertensive state (Conlon et al., 2005; Tabrizchi 
& Bedi, 2001). Several studies have been conducted in order to further understand the role 
of ENT in cardiovascular diseases (Chaudary et al., 2004; Li et al., 2011; Reyes et al., 2010; 
Rose et al., 2010). Adenosine seems to be a cardioprotective metabolite. Hypoxia and 
ischemia lead to a large increase in extracellular adenosine, which is released by 
cardiomyocytes. Extracellular adenosine activates G-protein coupled adenosine receptors 
linked to various signalling pathways, which initiate compensatory responses. Intracellular 
and extracellular levels of adenosine fluctuate, considerably, depending on the metabolic 
state of the heart, the flux of adenosine (down its concentration gradient), across the 
cardiomyocyte cell membrane, is facilitated by the ENT. These transporters are highly 
expressed in the cardiovascular system but very little is known about their role in 
cardiomyocyte physiology (Baldwin et al., 2004; Chaudary et al., 2004; Reyes et al., 2010). 
As previously mentioned, ENT are bidirectional, allowing adenosine to be released from 
cells (to act as an autocrine/paracrine hormone), or transported into the cell (to terminate 
receptor activation, or restore adenosine metabolite pools). Thus, cardiomyocyte adenosine 
physiology is dependent on the adenosine receptor profile, and on the presence and activity 
of the ENT. In the past years, ENT have been shown to be important in modulating the 
effects of adenosine in human epithelial cells. Moreover, a correlation was found between 
ENT1 and A1 adenosine receptor distribution in the brain, suggesting potential interactions 
and/or feedback between receptors and transporters. Nevertheless, there is an extensive 
literature on adenosine and adenosine receptor physiology in the cardiovasculature, 
whereas very little is known about ENT (Baldwin et al., 2004; Chaudary et al., 2004).  
ENT inhibitors, by virtue of their effect on extracellular adenosine concentrations, can also 
modulate a variety of physiological processes, potentially leading to therapeutic benefits. 
For example, by inhibiting nucleoside uptake into endothelial and other cells the coronary 
vasodilator draflazine substantially increases and prolongs the cardiovascular effects of 
adenosine. The latter exerts beneficial, cardioprotective effects in the ischaemic/reperfused 
myocardium mediated, at least in part, via activation of A1 and possibly also A3 receptors, 
probably involving the protein kinase C and mitochondrial KATP channels. Transport 
inhibitors have also potential value in the context of ischaemic neuronal injury: pre-
ischaemic administration of the pro-drug NBMPR phosphate has been shown to increase 
brain adenosine levels and reduce ischaemia-induced loss of hippocampal neurons in the 
rat. In a clinical setting, pharmacological inhibition of ENT, using drugs such as 
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dipyridamole, dilazep and draflazine, is used to promote cardiovascular health. However, 
despite the clinical relevance of ENT as drug targets, very little is known about them 
(Baldwin et al., 2004; Tabrizchi & Bedi, 2001; Takahashi et al., 2010). 
Recent studies have challenged the role of ENT in purine nucleoside-dependent physiology 
of the cardiovascular system. Rose and co-workers (2010), investigated whether the ENT1-
null mouse heart was cardioprotected in response to ischaemia. In that study, the authors 
observed that ENT1-null mouse hearts showed significantly less myocardial infarction 
compared with wild-type littermates, demonstrating that ENT1 activity may contribute to 
cardiac injury. A posterior study (Reyes et al., 2010), confirmed that isolated wild-type adult 
mouse cardiomyocytes express predominantly ENT1, which is primarily responsible for 
purine nucleoside uptake in these cells. However, ENT1-null cardiomyocytes exhibit 
severely impaired nucleoside transport and lack ENT1 transcript and protein expression. 
Adenosine receptor expression profiles and expression levels of ENT2, ENT3, and ENT4 
were similar in cardiomyocytes isolated from ENT1-null adult mice compared with 
cardiomyocytes isolated from wild-type littermates. Moreover, small interfering RNA 
knockdown of ENT1 in the cardiomyocyte cell line, mimics findings in ENT1-null 
cardiomyocytes. Taken together, the data from the study conducted by Rose and co-workers 
(2010), demonstrated that the absence of ENT1 plays an essential role in cardioprotection, 
most likely due to its effects in modulating purine nucleoside-dependent signalling and that 
the ENT1-null mouse is a powerful model system for the study of the role of ENT in the 
physiology of the cardiomyocyte. 
Other authors, determined that adenosine and inosine accumulate extracellularly during 
hypoxia/ischaemia and that both may act as neuroprotectors (Takahashi et al., 2010). In the 
spinal cord, there was pharmacological evidence for an extracellular adenosine levels 
increase during hypoxia, but no direct measurements of purine release have been done; 
furthermore, the efflux pathways and origin of extracellular purines are still not defined. 
Therefore, to characterize hypoxia-evoked purine accumulation, Takahashi and co-workers 
(2010), examined the effect of acute hypoxia on the extracellular levels of adenosine and 
inosine in isolated spinal cords from rats, and these authors found that both inhibitors of 
adenosine deaminase or ENT, abolished the hypoxia-evoked increase in inosine but not 
adenosine: extracellular level of inosine was about 10-fold higher than that of adenosine. 
These data suggest that hypoxia releases adenosine itself from intracellular sources, on the 
other hand, inosine formed intracellularly may be released through ENT (Takahashi et al., 
2010). 
Gestational diabetes has been associated with increased L-arginine transport and nitric 
oxide (NO) synthesis as well as a reduced adenosine transport in human umbilical vein 
endothelial cells. Adenosine increases endothelial L-arginine/NO pathway via A2 adenosine 
receptors in human umbilical vein endothelial cells, in normal pregnancies (Vasquez et al., 
2004; Vega et al., 2009) compared to the reduction in adenosine transport observed in veins 
of women with gestational diabetes. Additionally, an association between L-arginine 
transport and NO synthesis was also found. In fact, Vásquez and co-workers (2004), 
demonstrated that in gestational diabetes, stimulation of L-arginine transport and NO 
synthesis occurs with a reduction in adenosine transport in human umbilical vein 
endothelial cells. 
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The effect of gestational diabetes on the L-arginine/NO pathway may result from an 
increased extracellular adenosine level, due to low adenosine uptake as a consequence of a 
reduced hENT1mRNA expression. Accumulation of extracellular adenosine could activate 
A2A adenosine receptors, which leads to an increased expression of cationic amino acid 
transporter-1 (hCAT-1) mRNA, and of endothelial nitric oxide synthase (eNOS), mRNA or 
protein expression, an increased L-arginine transport activity, as well as, of the NO 
synthesis. The effect of gestational diabetes on adenosine and L-arginine transport involves 
activation of protein kinase C, and p42/44 MAPK pathways and increased the NO levels. 
Thus, the authors hypothesized the establishment of a functional link between adenosine 
transport and the L-arginine/NO pathway, governing the normal function of human fetal 
endothelium from gestational diabetic pregnancies (Vasquez et al., 2004; Vega et al., 2009). 
These results also highlight the physiological effects of purinoceptors, particularly of 
adenosine receptors, in the umbilical vein endothelium, in pathologies, where alterations of 
blood flow from the mother to the fetus (via the umbilical vein may occur), altering the 
normal supply of nutrients to the developing fetus, such as in intrauterine growth 
restriction, fetal hypoxia or gestational diabetes. Finally, these findings also demonstrate 
that gestational diabetes induces alterations in the phenotype of human fetal endothelium 
(Vasquez et al., 2004).  
It has been demonstrated that insulin inhibited elevated ENT1 expression in human 
umbilical arterial smooth muscle cells from pregnancies in diabetic subjects (Aguayo et al., 
2001). However this is probably due to the activation of adenylate cyclase rather than the 
effect of insulin on glucose metabolism. The effects of oral anti-diabetic agents on nucleoside 
transporters are rarely reported: Li and co-workers (2011), studied the effects of different 
oral anti-diabetic agents such as metformin, sulfonyureas, meglitinides and 
thiazolidinediones on nucleoside transporters; among them, only the thiazolidinedione 
troglitazone showed inhibitory effects on nucleoside transporters, but unfortunately it was 
withdrawn because of hepatic toxicity.  
To our knowledge, until the present date, only one study has been carried out to investigate 
the relationship between hypertension and nucleoside transporters. The binding of a ENT1 
probe [3H]NBMPR in membranes prepared from platelets, as well as renal, pulmonary, cardiac 
and brain tissues of Spontaneously Hypertensive Rats (SHR), was compared to those of age 
matched Wistar-Kyoto (WKY) controls (Williams et al., 1990). The number of [3H]NBMPR 
binding sites were higher in the kidneys of SHR but lower in platelets, whereas no difference 
was found in the heart, lung or brain. Age-dependent decreases were also observed in the 
heart and platelets of SHR and WKY. The results indicated that the expression of ENT1 
changed with age as well as with the pathogenesis of hypertension. Li and co-workers (2011), 
compared the expressions of nucleoside transporters in basilar arteries in SHR and WKY rats 
and they found that ENT1 and ENT2 were unaffected by hypertension. Interestingly, the 
mRNA expression of CNT2 was higher than that seen in WKY; nevertheless, whether the 
upregulation of CNT2 is a primary or secondary event in the development of hypertension is 
questionable. It has been speculated that the increase in the activities of ENT1 and CNT2 may 
reduce the availability of adenosine to its receptors, thereby weakening the vascular functions 
of adenosine. It may explain why patients with diabetes and hypertension suffer greater 
morbidity from ischemia and atherosclerosis (Li et al., 2011). 
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2. Mesenteric vessels 
The branches of the abdominal aorta are divided into parietal and visceral parts. The 
visceral arteries are in turn divided into paired and unpaired branches. The mesenteric 
artery is an elasto-muscular resistance vessel. In adult rats, for example WKY, the 
mesenteric artery branches from the abdominal aorta and is composed of five to seven 
concentric layers of smooth muscle cells, separated by three to four medial laminae. The 
medium is separated from the endothelial cells of the intima by the continuous internal 
elastic lamina and from the adventitia, which contains a few fibroblasts and nerve terminals, 
by the external elastic lamina  (McGuire et al., 1993; Sullivan et al., 2002). 
Three major unpaired branches exist: the celiac trunk, the superior mesenteric artery and the 
inferior mesenteric artery. Each has several major branches supplying the abdominal organs: 
the superior mesenteric artery, supplies the pancreas, small intestine and the colon, whereas 
the inferior mesenteric artery supplies the descending colon and rectum (Fig. 4). 
 
Fig. 4. Schematic representation of splanchnic circulation. Under normal resting conditions 
in humans, total hepatic blood flow is 1200 to 1400 mL/min (~100 mL/min/100g), which 
represents about 25% of cardiac output. Blood flow to the four lobes of the liver is derived 
from two major sources, the portal vein and the hepatic artery. The hepatic artery is a 
branch of the celiac axis and accounts for 25 to 30 percent of total hepatic blood flow and 45 
to 50 percent of the oxygen supply. The portal vein is a valveless afferent nutrient vessel of 
the liver that carries blood from the entire capillary system of the stomach, spleen, pancreas, 
and intestine (McGuire et al., 1993). 
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The mesenteric circulation plays an important role in maintenance of systemic blood 
pressure, and regulation of tissue blood flow. Actually, the entire splanchnic circulation can 
receive up to 60% of cardiac output and contains about one third of the total blood volume. 
Mesenteric arteries and veins have significant resistance and capacitance functions in the 
systemic circulation, respectively. In comparison to the associated veins, the mesenteric 
artery has a high resting basal tone mediated in part by a thicker layer of vascular smooth 
muscle (Kreulen, 2003). Constriction of the mesenteric artery is thought to increase total 
peripheral resistance in the systemic circulation greatly. In contrast, the mesenteric vein, 
contains fewer layers of vascular smooth muscle cells and are more compliant vessels. The 
function of these low pressure vessels is to store significant quantities of blood that can be 
utilized to maintain the central venous pool of blood and cardiac output. As such, the 
degree of vascular tone in mesenteric vasculature plays a major role in the regulation of 
systemic blood pressure and overall body hemodynamics (Ross & Pawlina, 2006). 
2.1 Vascular tonus regulation and physiology in mesenteric vessels 
The tone of the mesenteric artery and resistance blood vessels are mainly regulated by 
sympathetic adrenergic nerves through the release of neurotransmitter noradrenaline. It is also 
controlled by nonadrenergic noncholinergic nerves, and possibly by parasympathetic 
cholinergic nerves. Noradrenaline and adrenergic cotransmitters including neuropeptide Y, 
and ATP, act as a vasoconstrictor neurotransmitter for sympathetic nerves. While, dopamine, 
calcitonin gene-related peptide and acetylcholine act as a vasodilator neurotransmitter for 
adrenergic, nonadrenergic noncholinergic and cholinergic nerves, respectively. In the 
mesenteric circulation, these nerves containing various neurotransmitters and cotransmitters 
interact and modulate each other via feedback autoregulatory mechanisms and 
neuromodulation of various vasoactive substance to regulate vascular resistance (Takenaga & 
Kawasaki, 1999). In fact, net vascular tone in the mesenteric vasculature is under the influence 
of several key factors. These factors include locally acting and circulating hormones, intrinsic 
myogenic properties of the vessel, as well as neurotransmitters released from perivascular 
post-ganglionic sympathetic neurons. In general, the arteries and veins of the splanchnic 
circulation are richly innervated with sympathetic nerves that act to constrict these vessels. 
Maximal activation of the sympathetic constrictor nerves can produce an 80% reduction in 
blood flow to the splanchnic region (Morhrman & Heller, 2006). 
In vivo, sympathetic neurogenic influence of vascular tone is mediated by three 
neurotransmitters: neuropeptide Y, noradrenaline, and ATP make up the sympathetic triad 
of neurotransmitters. Perivascular neurons store the sympathetic neurotransmitters in 
synaptic vesicles and release these neurotransmitters from varicosities to act on 
postjunctional receptors on the vascular smooth muscle cells. The arrangement of the 
sympathetic neurons differs between arteries and veins. The nerve plexus for the mesenteric 
artery consists of a bundle of axons arranged in a mesh-like network with nerve fibres 
equally likely to run parallel or perpendicular to the longitudinal axis of the vessel. In 
contrast, in mesenteric vein the nerve plexus consists of single axons with a circumferential 
nerve fibre arrangement about the vessel. In both cases, the sympathetic neurotransmitters 
released cause depolarization of the nearby vascular smooth muscle cells. As a whole, 
activation the sympathetic postjunctional receptors mediates contraction of the vascular 
smooth muscle cells and, therefore, constriction of the artery or vein (Park et al., 2007). 
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In vitro, electrical field stimulation studies have found that upon stimulation of mesenteric 
perivascular nerves a measurable amount of noradrenaline is released (Bobalova & 
Mutafova-Yambolieva, 2001). Once released, noradrenaline can act on a variety of receptors 
on the vascular smooth muscle cells. Previous in vitro studies have found contractile 
responses to be mediated by activation of the α1 adrenoceptor in mesenteric arteries and 
both α1 and α2 adrenoceptors in the mesenteric vein (Perez-Rivera et al., 2007). These 
adrenoceptors are G-protein linked receptors that are coupled to an intracellular increase of 
inositol 1,4,5-triphosphate (IP3). Contraction of the smooth muscle is mediated by IP3 acting 
on sarcoplasmic reticulum receptors to release intracellular Ca2+ stores. Additional Ca2+ is 
taken up into the vascular smooth muscle cells following depolarization via L-type voltage-
gated calcium channels (Lee et al., 2001). 
Like noradrenaline, a measurable amount of ATP is released from perivascular sympathetic 
neurons when activated by electrical field stimulation (Bobalova & Mutafova-Yambolieva, 
2001). In vivo, ATP is thought to mediate neurogenic contractions of vascular smooth muscle 
by acting on various purinergic receptors present on the smooth muscle cells. The two 
subtypes of purinergic receptors are the P2X and P2Y receptors. The P2X receptors are ATP-
gated ion channels that cause an influx of Ca2+ into the smooth muscle cells from the 
extracellular environment (Donoso et al., 2004). Though there are several P2X receptor 
isoforms, there is evidence that vascular smooth muscle cells primarily express the P2X1 
receptors (Wang et al., 2002). P2X receptors are thought to be responsible for the excitatory 
junction potentials (rapid and short depolarization of vascular smooth muscle) present in 
mesenteric artery (Kreulen, 2003). In contrast, excitatory junction potentials are not present 
in mesenteric vein. This is largely thought to be the result of selective expression of only the 
P2Y receptor subtype in mesenteric vein (Mutafova-Yambolieva et al., 2000). The P2Y 
receptors mediate slower contractile responses than the P2X receptors, and are G-protein 
linked receptors that have similar intracellular effects as the α-adrenoceptors. The isoforms 
of the P2Y receptors that are thought to be expressed in vascular smooth muscle cells are the 
P2Y2 and the P2Y4 receptors (Galligan et al., 2001). 
Noradrenaline and ATP contract the mesenteric artery and the mesenteric vein through the 
activation of adrenergic and purinergic vascular smooth muscle receptors respectively. The 
use of selective adrenoceptor agonists and antagonists suggests that the α1 adrenoceptor is 
the primary adrenoceptor mediating responses to noradrenaline in these vessels. In 
addition, the data collected suggests that the P2X and/or the P2Y1 receptors contract the 
mesenteric artery, but do not mediate substantial contractile responses in rat mesenteric 
vein. Therefore, this data suggests that other purinergic receptors, such as the P2Y2 and the 
P2Y4 receptor subtypes, mediate vasoconstriction in these vessels in response to ATP. The 
Sympathetic Nervous System, is an important modulator of net vascular tone in mesenteric 
arteries and veins, and that sympathetic modulation of these vessels is an important 
regulator of the resistance function of mesenteric artery and the capacitance function of 
mesenteric vein. 
Splanchnic veins and venules account for most of the active capacitance responses in the 
circulation and are richly innervated by the Sympathetic Nervous System. In fact, it has been 
estimated that innervation to the non hepatic splanchnic organs accounts for half of the total 
noradrenaline released in the entire body. Therefore, the recent observations in Angiotensin 
II salt hypertension of neurogenically mediated increases, in whole body venous tone, 
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would best be explained by increased Sympathetic Nervous System activity to the splanchnic 
circulation. The splanchnic vascular resistance rises in proportion to the blood pressure, and 
the transvascular escape rate of plasma proteins is increased. Vascular resistance increases in 
the hepatosplanchnic circulation before any other bed in humans with borderline 
hypertension. Therefore, increased sympathetic activity to the splanchnic circulation may 
represent a common stage in the development of hypertension (King et al., 2007). 
The various animal models of hypertension show variable results, but in general support the 
concept that vascular resistance changes in the splanchnic organs are similar in direction 
and magnitude to pressure changes. These resistance changes appear to result from 
increased responsiveness of the arterioles to a variety of constrictor influences, and they 
may result from either structural or functional changes. Hypertension appears to alter 
splanchnic arteriolar permeability via a pressure-dependent mechanism. These vessels may 
also undergo degenerative histological changes. In addition to the resistive and exchange 
alterations, the capacitance function of splanchnic veins is reduced, probably via a structural 
change (Nyhof et al., 1983).  
Also, chronic hypertension is associated with resistance artery remodelling and mechanical 
alterations. A study by Briones and co-workers (2003), evaluated the role of elastin in 
vascular remodelling of mesenteric artery from SHR. When compared with WKY, the 
mesenteric artery of SHR showed: smaller lumen, decreased distensibility at low pressures, 
a leftward shift of the stress–strain relationship, redistribution of elastin within the internal 
elastic lamina leading to smaller fenestrae but no change in fenestrae number or elastin 
amount. Elastase incubation fragmented the structure of internal elastic lamina in a 
concentration-dependent fashion, abolished all the structural and mechanical differences 
between strains, and decreased distensibility at low pressures. Mesenteric artery 
remodelling and increased stiffness are accompanied by elastin restructuring within the 
internal elastic lamina and elastin degradation reverses structural and mechanical 
alterations of SHR mesenteric artery. Differences in elastin organisation are, therefore, a 
central element in small artery remodelling in hypertension (Briones et al., 2003).  
The rat superior mesenteric vein, which drains blood from the intestine, or the splenic vein, 
which drains from the spleen, is a capacitance vein. The blood flow in the superior mesenteric 
vein is the primary source of irrigation of the rat liver and this vein plays an important role in 
maintaining bile flow, bile acid excretion, and bilirubin conjugation and in preventing the 
precipitation of bile (possibly preventing hepatolithiasis) (Adachi et al., 1991). 
The splanchnic venous bed is the largest vascular bed in terms of capacitance because 50% 
of the intestinal blood volume is in the venules and small mesenteric veins (Dunbar et al., 
2000). Also, many animal studies have shown that the splanchnic bed is very responsive to 
baroreceptor and sympathetic stimulation (Haase & Shoukas, 1991, 1992; Shoukas & Bohlen, 
1990), pointing to this vascular bed as a primary source of blood volume changes. These 
studies have demonstrated that sympathetic stimulation of splanchnic veins and venules 
will cause them to constrict, leading to significant volume shifts out of this vascular bed. 
Consequently, changes in splanchnic venous capacitance can have large effects on venous 
filling pressure. Capacitance changes can occur through changes in both vessel compliance 
and unstressed vascular volume. One way to experimentally assess these changes is to 
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examine changes in the pressure-diameter relationships of individual vessels, particularly in 
the splanchnic regions of the body. The mesenteric veins are also critical in modulating 
cardiac filling through venoconstriction.  
The mesenteric circulation is regulated by multiple mechanisms and there is sufficient 
amount of aspects described in the literature that support the suspicion that local metabolic 
factors are especially important in the control of intestinal vasculature. Of these, adenosine, 
which is a mesenteric vasodilator, may be the messenger of the intestinal tissue to signal 
appropriate responses of the intestinal vessels. The evidence supporting the candidacy of 
this nucleoside as a local regulator of mesenteric circulation may be summarized, as follows: 
adenosine is present in the tissue of the gut in measurable quantities; exogenous adenosine 
is a powerful dilator of mesenteric resistance vessels; blockade of adenosine receptors in the 
mesenteric circulation interferes significantly with three autoregulatory phenomena, i.e., 
postprandial hyperaemia, pressure-flow autoregulation, and reactive hyperaemia (Jacobson 
& Pawlik, 1992). 
3. Adenosinergic system and hypertension 
Some lines of investigation have already used both these models to study the role of 
adenosine in hypertension. For example, in 1987, Jackson performed an interesting assay, 
where the author compared the in vivo role of adenosine, as a modulator of noradrenergic 
neurotransmission, in the SHR and WKY. In the in situ blood-perfused rat mesentery, 
vascular responses to sympathetic periarterial nerve stimulation, and to exogenous 
noradrenaline, were enhanced in SHR compared with WKY. In both SHR and WKY, 
vascular responses to periarterial nerve stimulation were more sensitive to inhibition by 
adenosine, than were responses to noradrenaline. At matched base-line vascular responses, 
compared with WKY, SHR were less sensitive to the inhibitory effects of adenosine on 
vascular responses to periarterial nerve stimulation, but SHR and WKY were equally 
sensitive with respect to adenosine-induced inhibition of responses to noradrenaline. 
Antagonism of adenosine receptors with 1,3-dipropyl-8-p-sulfophenylxanthine, shifted the 
dose-response curve to exogenous adenosine six-fold to the right, yet did not influence 
vascular responses to periarterial nerve stimulation or noradrenaline in either SHR or WKY. 
Furthermore, periarterial nerve stimulation did not alter either arterial or mesenteric venous 
plasma levels of adenosine in SHR or WKY, and plasma levels of adenosine in both strains 
were always lower than the calculated threshold level required to attenuate 
neurotransmission. According to these findings, the author concluded that in vivo 
exogenous adenosine interferes with noradrenergic neurotransmission in both SHR and 
WKY; SHR are less sensitive to the inhibitory effects of exogenous adenosine on 
noradrenergic neurotransmission than are WKY; endogenous adenosine does not play a role 
in modulating neurotransmission in either strain under the conditions of this study; and 
enhanced noradrenergic neurotransmission in the SHR is not due to defective modulation of 
neurotransmission by adenosine (Jackson, 1987). 
Other studies have found differences in blood vessels when comparing SHR and WKY (Cox, 
1979; Gisbert et al., 2002; Leal et al., 2008; Lee, 1987); Rocha-Pereira et al., 2009). Findings 
from the study by Gisbert and co-workers (2002), showed that the population of 
constitutively active α1D-adrenoceptors is significantly increased in aorta and mesenteric 
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artery from adult SHR when compared to WKY - these results verify that the vessels in 
question, from hypertensive animals, have an increased population of constitutively active 
receptors as well as an increased functionality of the α1D-subtype, with respect to 
normotensive animals. Other studies (Villalobos-Molina & Ibarra, 1999; Villalobos-Molina et 
al., 1999; Xu et al., 1998), highlighted the importance of the α1D-adrenoceptor in the pathology 
of hypertension, suggesting that, it appears first in the vasculature, followed by a rise in blood 
pressure. α1D-adrenoceptors can be found on smooth muscle cells and the activation of these 
receptors by noradrenaline (released by sympathetic postganglionic terminals), conduce 
mainly to vasoconstriction. These can lead to an increase in blood pressure playing, therefore, 
a role in the development of hypertension observed in SHR animals. The opposite effect to the 
contraction of smooth muscle can occur as a result of adenosine acting on A2 adenosine 
receptors, thus causing smooth muscle relaxation. The levels of extracellular adenosine, which 
can act on those receptors to produce this effect, can be altered by ENT. These transporters 
play a role in determining the levels of adenosine available extracellularly and hence the extent 
of vasodilation which can occur (Rang et al., 2007).  
On the other hand, previous studies have shown that the vasodilatory response to 
adenosine and its analogues is weakened in hypertension and in other pathological 
conditions affecting blood vessels (Lockette et al., 1986; Luscher et al., 1987). Lüscher and 
co-workers (1987) investigated the effects of antihypertensive therapy on hypertensive 
rats and their findings demonstrated a prevention or reversal of decreased endothelium-
dependent relaxations in response to agonists, suggesting that antihypertensive treatment 
normalizes endothelium-dependent relaxations. It was, therefore, proposed that 
antihypertensive treatment may be important in preventing cardiovascular complications 
in hypertensive individuals. A possible explanation for the attenuated vasodilatory 
response to adenosine in hypertension can be linked to the levels of adenosine receptors 
and their functionality in hypertensive models. Vasodilation of blood vessels occurs via 
the activation of adenosine receptors by adenosine and so an alteration in these receptors 
can result in a modified vasodilatory response (Rocha-Pereira et al., 2009). This hypothesis 
can be associated with adenosine transporters, which are partly responsible for making 
adenosine available to adenosine receptors. It is, therefore, legitimate to hypothesize that 
an increase or decrease in transporter population could indirectly alter the physiology of 
the adenosinergic system and, contributing indirectly to the contractility of blood vessels 
and conducing to an elevated blood pressure (correspondent to the pathologic situation of 
hypertension). 
4. Nucleoside transporters as therapeutic tools – Future perspectives 
Nucleoside derived drugs or nucleobase analogues are being developed and investigated 
for a number of different applications, in order to pursue a better and more efficient way of 
treating several diseases. The studies conducted in several other conditions might shed 
some light in this challenging pathway, as promising results have already been published, 
for example in cancer and infection by Human Immunodeficiency Virus (Cano-Soldado et 
al., 2008; Damaraju et al., 2003; Endo et al. 2007; Hyde et al., 2001; Kong et al., 2004; Molina-
Arcas et al., 2005, 2009; Ritzel et al., 2001; Yao et al., 2002), chronic pain and inflammation 
(Eltzschig et al., 2005; Li et al., 2009, 2011; Reyes et al., 2010). 
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The amount of research being done in these past years is indicative of the interest and 
potential that the area of ENT have in many scientific fields, especially in what concerns its 
role in a pharmacological perspective. Hopefully, in the future, as the knowledge increases 
and the mechanisms involving these transporters are better understood, the application of 
ENT will have an impact, particularly, in cardiovascular diseases, such as hypertension.  
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Clinical Impact of Cardiovascular Physiology and Pathophysiology.
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